Filtrer vos résultats
- 2
- 1
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Clinical Microbiology and Infection, 2021, 27 (12), pp.1826-1837. ⟨10.1016/j.cmi.2021.05.020⟩
Article dans une revue
hal-03364426v1
|
||
|
Performance of the ROX index to predict intubation in immunocompromised patients receiving high-flow nasal cannula for acute respiratory failureAnnals of Intensive Care, 2021, 11, pp.17. ⟨10.1186/s13613-021-00801-z⟩
Article dans une revue
hal-03122977v1
|
||
|
Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trialJournal of Antimicrobial Chemotherapy, 2021, 76 (12), pp.3303-3309. ⟨10.1093/jac/dkab307⟩
Article dans une revue
hal-03436464v1
|